Global Duchenne Muscular Dystrophy Market Insights, Epidemiology and Forecast 2019-2028 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 9, 2019--The “Duchenne Muscular Dystrophy - Market Insights, Epidemiology and Market Forecast - 2028” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Duchenne Muscular Dystrophy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Duchenne Muscular Dystrophy (DMD) from 2017 to 2028 segmented by seven major markets.
The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017-2028
Duchenne Muscular Dystrophy Epidemiology
The Duchenne Muscular Dystrophy (DMD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by diagnosed prevalent population, age-specific prevalent population, mutation-specific prevalent population and prevalent population of associated comorbidities in Duchenne Muscular Dystrophy.
The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to the publisher, the prevalent population of Duchenne Muscular Dystrophy (DMD) was estimated to be 31,432 [7MM] in 2018. United States accounts for the highest DMD cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries France had the highest prevalent patient population of Duchenne Muscular Dystrophy, followed by Italy.
Duchenne Muscular Dystrophy Drug Chapters
This segment of the Duchenne Muscular Dystrophy report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Current standard of care includes the use of corticosteroids to prolong ambulation and to delay the onset of secondary complications. Early use of cardioprotective agents, noninvasive positive pressure ventilation, and other supportive strategies has improved the life expectancy and health-related quality of life for many young adults with DMD. Treatments include the standard care for DMD along with the new upcoming therapeutic strategies including Genetic Therapies, Cell therapy using muscle precursor cells or stem cells, Membrane stabilization and upregulation of cytoskeletal proteins and Treatment of secondary cascades.
Glucocorticoids, more precisely prednisone and deflazacort, form main drug treatment for DMD. Deflazacort is an oxazoline derivate of prednisone. Deflazacort shows more bone-sparing and carbohydrate-sparing properties with less weight-gain effects and improves strength and function. Therefore, Deflazacort becomes the preferred choice over prednisone due to limited side effects and the beneficial properties of muscle sparing and delayed scoliosis progression.
The current US market possess only two approved products namely Emflaza and Exondys 51 commercialized by Marathon Pharmaceuticals/ PTC Therapeutics and Sarepta Therapeutics respectively. The recently approved products are known to capture the current market. Detailed chapters for all of these drugs, along with the upcoming therapies i.e., Golodirsen (SRP-4053, Sarepta Therapeutics), Talditercept alfa (also known as RO 6206, RO 7239361, BMS-986089), Idebenone (also known as Catena; CV-2619; Raxone) by Santhera Pharmaceuticals as well as another promising candidate i.e., Givinostat have been covered in the report.
Duchenne Muscular Dystrophy Market Outlook
The Duchenne Muscular Dystrophy (DMD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Treatments include the standard care for DMD along with the new upcoming therapeutic strategies including Genetic Therapies, Cell therapy using muscle precursor cells or stem cells, Membrane stabilization and upregulation of cytoskeletal proteins and Treatment of secondary cascades. The medical management for Duchenne Muscular Dystrophy (DMD) comprises several aspects such as Cardiac care, Diet, Exercise, Respiratory Care, Braces, Spinal curvatures. The treatment strategy is also encompasses supportive treatment and Psychosocial management. DMD is a multilevel/multisystem disease. The medical care of a patient who has DMD and his family is not complete without support for their psychosocial wellbeing.
According to the publisher, the global market of Duchenne Muscular Dystrophy (DMD) was estimated to be USD 1,022 million in 2018. The United States accounts for the largest market size of Duchenne Muscular Dystrophy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among the EU5 countries, France had the highest market size with 84.15 Million in 2018, while Spain had the lowest market size of Duchenne Muscular Dystrophy (DMD). The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028.
Duchenne Muscular Dystrophy Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Duchenne Muscular Dystrophy (DMD). Owing to the positive outcomes of the several products during the developmental stage by key players such as Santhera Pharmaceutical, Catabasis Pharmaceuticals, Italfarmaco etc. has a potential to create a significant positive shift in the Duchenne Muscular Dystrophy (DMD) Market Size.
Duchenne Muscular Dystrophy Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Duchenne Muscular Dystrophy Report Key Strengths
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Duchenne Muscular Dystrophy Report Assessment
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This report will help to develop Business Strategies by understanding the trends shaping and driving the Duchenne Muscular Dystrophy market.
- Organize sales and marketing efforts by identifying the best opportunities for Duchenne Muscular Dystrophy market.
- To understand the future market competition in the Duchenne Muscular Dystrophy market.
- Marathon Pharmaceuticals
- PTC Therapeutics
- Sarepta Therapeutics
- Santhera Pharmaceuticals
- Catabasis Pharmaceuticals
- Nippon Shinyaku
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/rsmxy
View source version on businesswire.com:https://www.businesswire.com/news/home/20190509005442/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs ,Musculoskeletal Disorders Drugs
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/09/2019 06:20 AM/DISC: 05/09/2019 06:20 AM